drugset / Trial / NCT03129113

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

NCT03129113

RandomizedFactorialSingle-blindTreatment

Summary

This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks. Sponsored by University College London Coordinated by MRC Clinical Trials Unit at UCL

Timeline

Start
2017-03-01
Primary completion
2020-11-05
Completion
2020-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified Oral
Subject Metformin Small molecule 500 mg Oral